Evidence map›Paper›PMID 31240976›Full record

SynthesisJournal of the American Heart Association2019

Effects of the Angiotensin-Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta-Analysis.

Yiwen Wang, Ran Zhou, Chi Lu, Qing Chen, Tongda Xu, Dongye Li

Registry-linked trialOpen access · goldAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of the American Heart Association, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07270367 (Finerenone and Cardiac Remodeling), which is not on this map. Cited by 131 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed, 10 pooled it
17.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07270367 phase3not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Finerenone and Cardiac Remodeling: A Randomized, Double- Blind, Placebo-Controlled Study to Evaluate The Effects of Finerenone on Ventricular Remodeling

TypeinterventionalSponsorSubodh VermaRan2025 to 2030Enrolled156ConditionsHeart FailureArmsFinerenone, Placebo
3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 10 syntheses or guidelines pooled it, 230 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yiwen Wang1 Institute of Cardiovascular Disease Research Xuzhou Medical University Xuzhou Jiangsu China.
Ran Zhou1 Institute of Cardiovascular Disease Research Xuzhou Medical University Xuzhou Jiangsu China.
Chi Lu1 Institute of Cardiovascular Disease Research Xuzhou Medical University Xuzhou Jiangsu China.
Qing Chen2 Department of Cardiology The Affiliated Hospital of Xuzhou Medical University Xuzhou Jiangsu China.
Tongda Xu2 Department of Cardiology The Affiliated Hospital of Xuzhou Medical University Xuzhou Jiangsu China.
Dongye Li1 Institute of Cardiovascular Disease Research Xuzhou Medical University Xuzhou Jiangsu China.
Xuzhou Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background The angiotensin-receptor neprilysin inhibitor (ARNI) sacubitril/valsartan was shown to be superior to the angiotensin-converting enzyme inhibitor enalapril in terms of reducing cardiovascular mortality in the PARADIGM-HF (Prospective Comparison of ARNI with angiotensin-converting enzyme inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) study. However, the impact of ARNI on cardiac reverse remodeling (CRR) has not been established. Methods and Results We conducted a meta-analysis to compare the effects of ARNI versus angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on CRR indices. We searched databases for studies published between 2010 and 2019 that reported CRR indices following ARNI administration. Effect size was expressed as mean difference (MD) with 95% CIs. Twenty studies enrolling 10 175 patients were included. ARNI improved functional capacity in patients with heart failure (HF) and a reduced ejection fraction (EF), including increasing New York Heart Association functional class (MD -0.79, 95% CI -0.86, -0.71) and 6-minute walking distance (MD 27.62 m, 95% CI 15.76, 39.48). ARNI outperformed angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in terms of CRR indices, with striking changes in left ventricular EF, diameter, and volume. However, there were no significant improvements in indices except left ventricular mass index (MD -3.25 g/m

Indexed as

Atrial RemodelingVentricular RemodelingAminobutyratesAngiotensin Receptor AntagonistsBiphenyl CompoundsDrug CombinationsHeart FailureHumansStroke VolumeTetrazolesTreatment OutcomeValsartanWalk TestAminobutyratesAngiotensin Receptor AntagonistsBiphenyl CompoundsDrug Combinationssacubitril and valsartan sodium hydrate drug combinationTetrazolesValsartanangiotensin‐receptor neprilysin inhibitorcardiac reverse remodelingend‐diastolic dimensionheart failure with a reduced ejection fractionmeta‐analysis

Identifiers

PMID31240976
PMCPMC6662364
OpenAlexW2954586029

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.